BioAmber (NYSE: BIOA) reported Q2 EPS of ($0.26), $0.04 worse than the analyst estimate of ($0.22). Revenue for the quarter came in at $3.7 million versus the consensus estimate of $3.85 million.

For earnings history and earnings-related data on BioAmber (BIOA) click here.